NEW YORK, Oct. 27, 2015 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of TriVascular Technologies, Inc. ("TriVascular" or the "Company") (NASDAQ: TRIV) concerning the proposed acquisition of the Company by Endologix, Inc. ("Endologix").
Under the terms of the offer, the TriVascular would acquire Endologix in a transaction valued at approximately $211 million. Pursuant to the deal, TriVascular stockholders would receive a combination of cash and stock valued at approximately $9.10 per share. According to Yahoo Finance, at least one analyst has set a target price for TriVascular stock of $13.00 per share.
Our investigation concerns whether the TriVascular board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company stockholders.
If you own TriVascular shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Benjamin I Sachs-Michaels, Esq.
Robert I. Harwood, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
Email: [email protected]
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
Attorney Advertising. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
SOURCE Harwood Feffer LLP